Publications by authors named "Debra Richardson"

Claim this Profile
C
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].
Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed

Gynecol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics.
Samrita Dogra, Laura Adhikari, Doris M Benbrook, Jacqueline A Bohn, Anthony Burgett, Debra L Richardson

Mol Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
Melissa M Hardesty, Thomas C Krivak, Gail S Wright, Erika Hamilton, Evelyn L Fleming, Debra L Richardson

Gynecol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
Debra L Richardson, Julia C F Quintanilha, Natalie Danziger, Gerald Li, Ethan Sokol

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed

Gynecol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Charles A Leath, Wei Deng, Loren K Mell, Debra L Richardson, Joan L Walker

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.
Oladapo O Yeku, Minal Barve, Winston W Tan, Judy Wang, Amita Patnaik, Debra L Richardson

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).
Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, Iakov I Davydov, Debra L Richardson

BMC Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
Devalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, Mary F Mulcahy, Aparna Kalyan, Debra L Richardson

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le

J Immunother Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Kan Yonemori, Valentina Boni, Kim Gun Min, Tarek M Meniawy, Janine Lombard, Debra L Richardson

Gynecol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892).
Sarah E Taylor, Sarah Behr, Kristine L Cooper, Haider Mahdi, Denise Fabian, Debra L Richardson

Cancer Chemother Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
Debra L Richardson, Julia C F Quintanilha, Natalie Danziger, Gerald Li, Ethan Sokol

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.
Babar Bashir, Judy S Wang, Gerald Falchook, Elisa Fontana, Hendrik-Tobias Arkenau, Debra L Richardson

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog, Debra Richardson

Int J Gynecol Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Debra L Richardson, Kathleen N Moore, Ignace Vergote, Lucy Gilbert, Lainie P Martin

Gynecol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Vicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, Erika Hamilton, Toon Van Gorp, Debra L Richardson

Gynecol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma

Clin Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Ignace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, Giorgio Valabrega, Toon Van Gorp, Debra L Richardson

J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Robert W Holloway, Premal Thaker, Alberto A Mendivil, Sarfraz Ahmad, Ahmed N Al-Niaimi, Debra Richardson

Int J Gynecol Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
Linda R Duska, Dmitriy Zamarin, Erica Hamilton, Amit Oza, Gini Fleming, Debra L Richardson

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Debra L Richardson, Ramez N Eskander, David M O'Malley

JAMA Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emerging use of antibody-drug conjugates in ovarian cancer.
Debra L Richardson

Clin Adv Hematol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology.
Debra L Richardson

Gynecol Oncol Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in antibody-drug conjugates for gynecologic malignancies.
Joan Tymon-Rosario, Megan Gorman, Debra L Richardson, Christina Washington, Alessandro D Santin

Curr Opin Obstet Gynecol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis